News

BMO Capital Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
The Malaysian Reserve15h
SRPT INVESTOR NOTICE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: ...
Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2025.